John C. Morris, MD, Principal Investigator Washington University in St. Louis

The Dominantly Inherited Alzheimer’s Network (DIAN), an international research consortium, is organized to study the basic causes of Alzheimer’s disease (AD).  Established by a cooperative agreement award (U01 AG032438) from the National Institute on Aging (Bethesda, MD, USA), DIAN enrolls individual members of families in which there is a known genetic cause (mutation in the APP, PSEN1, or PSEN2 genes) for AD.  These study participants undergo comprehensive assessments at a DIAN performance site* to discover what indicators of brain changes related to AD may occur before the onset of dementia and in what order the indicators appear.  Although DIAN is not presently developed to test potential therapies for AD, the ultimate goal is develop the infrastructure and knowledge base to advance the evaluation of drugs that may be truly effective in treating or even preventing AD.

To contact us about participating in DIAN, click here.

 

   * Performance sites:

 
Australian Consortium

Consortium leader: Peter Schofield


Prince of Wales Medical Research Institute & University of New South Wales, Sydney
Site Leader:  Peter Schofield

 

Mental Health Research Institute of Victoria & University of Melbourne, Melbourne
Site Leader:  Colin Masters

 

Edith Cowan University, Perth
Site Leader:  Ralph Martins

 

Brigham & Women’s Hospital/Massachusetts General Hospital
Site leader: Reisa Sperling

 

Brown University/Butler Hospital
Site Leader:  Stephen Salloway

 

Columbia University
Site leader: Richard Mayeux

 

Indiana University
Site leader: Bernardino Ghetti

 

University College, London/Inst. of Neurology Queen Square
Site leader: Martin Rossor

 

University of California, Los Angeles
Site leader: John Ringman

 

Washington University
Site leader: Randall Bateman